Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID‐19 cases treated with sotrovimab in the community in England
Sign Up to like & getrecommendations! Published in 2022 at "Influenza and Other Respiratory Viruses"
DOI: 10.1111/irv.13150
Abstract: There are concerns that sotrovimab has reduced efficacy at reducing hospitalisation risk against the BA.2 sub‐lineage of the Omicron SARS‐CoV‐2 variant. We performed a retrospective cohort (n = 8850) study of individuals treated with sotrovimab in the… read more here.
Keywords: risk hospitalisation; hospitalisation; risk; sotrovimab community ... See more keywords